文献速递结核与非结核分枝杆菌

左氧氟沙星治疗儿童耐药结核病的药代动力学与最优给药:个体患者数据荟萃分析

Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该个体患者数据荟萃分析纳入5项研究、242名儿童,用非线性混合效应模型分析左氧氟沙星药代动力学,并按成人AUC24目标101 mg·h/L进行模拟。结果显示,当前WHO推荐剂量在体重<24 kg及<10岁儿童中暴露低于目标,需按体重带将剂量调整至>20 mg/kg。

要点

  • 当前WHO推荐剂量在体重<24 kg及<10岁儿童中左氧氟沙星暴露低于成人AUC目标。
  • 按模型优化,分散片需16-33 mg/kg、非分散片需16-50 mg/kg方可达到AUC目标。
  • 作者认为需修订体重带给药指南,采用>20 mg/kg剂量以保证足够暴露。

核心结论

  • 需修订体重带给药指南,采用>20 mg/kg的左氧氟沙星剂量以确保儿童耐药结核病治疗达到足够暴露。
  • 尚需进一步研究确定这些较高剂量的安全性和耐受性。

研究设计与样本

  • 个体患者数据荟萃分析,汇总5项研究的左氧氟沙星浓度与人口学数据,采用非线性混合效应模型分析,并用模拟评估WHO推荐剂量与模型优化剂量。
  • 纳入242名儿童,年龄2.8岁(范围0.2-16.8岁)。

主要发现

  • 13 kg儿童的表观清除率为3.16 L/h。
  • 年龄影响清除率,出生时达50%成熟,8月龄时达90%成熟。
  • 非分散片相比分散片的表观口服生物利用度低29%。
  • 当前WHO推荐剂量下,体重<24 kg及<10岁儿童的中位暴露低于AUC目标,约为成人暴露的一半。
  • 分散片需16-33 mg/kg、非分散片需16-50 mg/kg的模型优化剂量方能达到AUC目标且不明显超过成人中位Cmax。

关键数值与推荐

  • 目标为当前成人标准剂量下中位成人AUC24 101 mg·h/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究确定较高剂量的安全性和耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Each year 25 000-32 000 children develop rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB), and many more require preventive treatment. Levofloxacin is a key component of RR/MDR-TB treatment and prevention, but the existing pharmacokinetic data in children have not yet been comprehensively summarized. We aimed to characterize levofloxacin pharmacokinetics through an individual patient data meta-analysis of available studies and to determine optimal dosing in children. METHODS: Levofloxacin concentration and demographic data were pooled from 5 studies and analyzed using nonlinear mixed effects modeling. Simulations were performed using current World Health Organization (WHO)-recommended and model-informed optimized doses. Optimal levofloxacin doses were identified to target median adult area under the time-concentration curve (AUC)24 of 101 mg·h/L given current standard adult doses. RESULTS: Data from 242 children (2.8 years [0.2-16.8] was used). Apparent clearance was 3.16 L/h for a 13-kg child. Age affected clearance, reaching 50% maturation at birth and 90% maturation at 8 months. Nondispersible tablets had 29% lower apparent oral bioavailability compared to dispersible tablets. Median exposures at current WHO-recommended doses were below the AUC target for children weighing <24 kg and under <10 years, resulting in approximately half of the exposure in adults. Model-informed doses of 16-33 mg/kg for dispersible tablets or 16-50 mg/kg for nondispersible tablets were required to meet the AUC target without significantly exceeding the median adult Cmax. CONCLUSIONS: Revised weight-band dosing guidelines with doses of >20 mg/kg are required to ensure adequate exposure. Further studies are needed to determine safety and tolerability of these higher doses.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. White YN, Solans BP, Denti P, et al. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Clin Infect Dis. 2024. PMID: 38340060. doi:10.1093/cid/ciae024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。